The 1998 growth-hormone trial provides an important counterweight to broad cognitive-enhancement claims. Its result should be reported without either exaggerating a benefit or turning a null result into a universal verdict. Primary paper
Trial findings
Forty men with adult-onset growth-hormone deficiency and a history of pituitary disease were randomized to growth hormone or placebo in an 18-month double-blind trial. Standardized cognitive and wellbeing tests were used. Baseline mean cognitive scores were within normal limits, and overall IQ was above the normative mean. The investigators reported no significant improvement in cognition or quality of life after treatment. Primary paper
Our appraisal: start with baseline performance
An intervention can be tested in people with a biological deficiency without their performance on every functional test being impaired. Those are different definitions. A careful summary should not assume a cognitive deficit solely from a hormone diagnosis.
For an illustrative example, a hypothetical group could have an abnormal laboratory marker but average performance on a memory test. Improving the laboratory marker would not mathematically require improvement on the test. The two outcomes must be measured and interpreted separately.
Baseline performance also helps frame the research question. Testing restoration of an impaired function is not identical to testing enhancement above an already normal range. This distinction is useful when evaluating headlines that move between deficiency treatment and enhancement in otherwise healthy people.
How to read the negative result
A nonsignificant result should prompt inspection of the effect estimate and its uncertainty, not simply a label of “no effect.” Our full-paper checklist includes sample-size justification, test reliability, prespecified outcomes, missing follow-up, and whether multiple cognitive measures were handled appropriately.
The conclusion also remains tied to the enrolled population, treatment conditions, and observation period. It cannot settle every question involving growth hormone, all causes of deficiency, all age groups, or every quality-of-life instrument. At the same time, those limits are not permission to claim a benefit that this trial did not demonstrate.
Frequently asked questions
Were healthy volunteers seeking enhancement enrolled?
No. Participants had adult-onset deficiency and pituitary disease histories.
Were women included?
The reported sample consisted of men.
Were average baseline cognitive scores abnormal?
The abstract reports means within normal limits.
Was a significant cognitive benefit demonstrated?
No, not in the reported 18-month trial.
Does that prove every possible effect is zero?
No. Precision and applicability still require appraisal.
Does a different biological outcome prove cognitive improvement?
No. Each outcome requires evidence matched to its claim.
What source was used?
The indexed primary abstract and record. This historical appraisal is not a current prescribing recommendation.